[1]Li LJ, Liu XL, Xu XW, et al.Comparison of plasma exchange with different membrane pore sizes in the treatment of severe viral hepatitis. Ther Apher Dial. 2005; 9(5):396-401.
[2]Nakae H, Igarashi T, Tajimi K.Selective plasma exchange with dialysis in patients with acute liver failure. Ther Apher Dial. 2012; 16(5):467-71.
[3]Flaum MA, Cuneo RA, Appelbaum FR, et al.The hemostatic imbalance of plasma-exchange transfusion. Blood. 1979; 54:694-702.
[4]Orlin JB, Berkman EM.Partial plasma exchange using albumin replacement: Removal and recovery of normal plasma constituents. Blood. 1980; 56:1055-1059.
[5]Chirnside A, Urbaniak SJ, Prowse CV, et al.Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol. 1981; 48:627-634.
[6]Levy JH, Goodnough LT.How I use fibrinogen replacement therapy in acquired bleeding. Blood. 2015; 26; 125(9):1387-93.
[7]Kaplan AA.Therapeutic Plasma Exchange: A Technical and Operational Review. J Clin Apher. 2013; 28(1):3-10.
[8]Ohkubo A, Kurashima N, Nakamura A, et al.Solute removal capacity of high cut-off membrane plasma separators. Ther Apher Dial. 2013; 17(5):484-9.
[9]Ohkubo A, Okado T, Kurashima N, et al.Removal Characteristics of Immunoglobulin G Subclasses by Conventional Plasma Exchange and Selective Plasma Exchange. Ther Apher Dial. 2015; 19(4):361-6.
[10]Ohkubo A, Okado T, Miyamoto S, et al.Fibrinogen Reduction During Selective Plasma Exchange due to Membrane Fouling. Ther Apher Dial. 2017; 21(3):232-237.
[11]Miyamoto S, Ohkubo A, Seshima H, et al.Removal Dynamics of Autoantibodies, Immunoglobulins, and Coagulation Factors by Selective Plasma Exchange on Three Consecutive Days. Ther Apher Dial. 2018; 22(3):255-260.
[12]McLeod BC, Sniecinski I, Ciavarella D, et al.Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion. 1999; 39(3):282-8.
[13]Ohkubo A, Okado T.Selective plasma exchange. Transfus Apher Sci. 2017; 56(5):657-660.
[14]Nakae H, Fukuda H, Okuyama M, Igarashi T.Selective Plasma Exchange for Critically Ill Patients Accompanied With Thrombocytopenia. Ther Apher Dial. 2016; 20(4):339-41.
[15]Milliner DS, Shinaberger JH, Shuman P, Coburn JW.Inadvertent aluminum administration during plasma exchange due to aluminum contamination of albumin-replacement solutions. N Engl J Med. 1985; 312(3):165-7.
[16]Schwartz J, Padmanabhan A, Aqui N, et al.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016; 31(3):149-338.
[17]李兰娟.肝衰竭与李氏人工肝进展.中华临床感染病杂志. 2017; 10(2):91-94.
[18]黄建荣, 杨芊, 陈月美, 徐小微, 李兰娟.选择性血浆置换治疗慢性重型肝炎的临床观察.中华医学会第二届全国暨国际肝衰竭与人工肝学术会议(2003-08-01杭州)
[19]Miyamoto S, Ohkubo A, Seshima H, et al.Removal Dynamics of Immunoglobulin and Fibrinogen by Conventional Plasma Exchange, Selective Plasma Exchange, and a Combination of the Two. Ther Apher Dial. 2016; 20(4):342-7.
[20]Naganuma T, Takemoto Y, Masuda A, et al.Efficacy of selective plasma exchange as pretransplant aphresis in ABO-incompatible kidney transplantation. Nephrology. 2016; 21Supplement 2: 130-130.
[21]Gungor H.K, Saral S, Gundogdu M, et al. Induction of remission and cytokine levels in pemphigus after selective plasma exchange therapy. Experimental Dermatology.2016; 25Supplement 4: 21-22.(Meeting Abstract: P051)
[22]Fukushima K, Yoshimura S, Shiraishi H, et al.Effectiveness of selective plasma exchange therapy (SePE) in patients with myasthenia gravis. Journal of the Neurological Sciences. 2017; 381 Supplement S; : 276-276.(Meeting Abstract: 758)
[23]Nasu K, Hanafusa N, Nangaku M.Selective plasma exchange can reduce auto-antibodies in patients with bullous pemphigoid without affecting factor XIII and fibrinogen.J Clin Apher. 2017; 32(6):589-591.
[24]Hutchison CA, Cockwell P, Stringer S, et al.Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011; 22(6):1129-36.
[25]Burnette BL, Leung N, Rajkumar SV.Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011; 364(24):2365-6.
[26]Kawabe M, Yamamoto I, Katsuma A, et al.Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange. CEN Case Rep. 2016; 5(2):232-237.
[27]Lysenko Irina B, Guskova Nailya, Kit Oleg Ivanovich, et al.Paraprotein levels in assessing effectiveness of polychemotherapy plus selective plasma exchange for multiple myeloma patients. Journal of Clinical Oncology 35, no. 15_suppl - published online before print. Published online May 30, 2017.
[28]Kanda M, Sanada S, Kowata H, et al.Renal Improvement With Molecular-Selective Plasma Exchange in a Patient With Bence-Jones Type Multiple Myeloma. Ther Apher Dial. 2016; 20(4):420-2.
[29]Nakae H, Hattori T, Igarashi T, et al.Removal of toxic substances by a selective membrane plasma separator. Ther Apher Dial. 2014; 18(3):265-71.
